The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...

The US FDA has added new warnings to the Pfizer and Moderna COVID-19 vaccines about a rare heart condition that mostly affects young men.

This summary encapsulates recent health updates including Carmat's insolvency filing, Bayer's glyphosate litigation in the U.S. Supreme Court, FDA's label revisions for ADHD stimulants, a U.S. House ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Recent health-related developments highlight significant shifts in the pharma industry and governance: France's Carmat files ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.